Sera: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Test volume increased approximately fivefold from the first quarter of 2026.

  • Florida Medicaid coverage expanded access to nearly 90,000 annual births.

  • Management expects operating expenses to stay flat or decline in 2027.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings conference call, held on Nov. 4, 2026, Sera (NASDAQ:SERA) reported that test volume for PreTRM, its blood test that predicts preterm birth risk, increased approximately fivefold from the first quarter of 2026. Expanding state Medicaid coverage and physician adoption are driving early commercial scale for the maternal health company.

Three key takeaways stand out for long-term investors.

1. Florida and Illinois Medicaid Expansion Validates State Coverage Playbook

State Medicaid programs pay for roughly 40% to 43% of U.S. births, making government policy the primary catalyst for diagnostic adoption. Securing fee schedule pricing in major markets allows the business to convert regulatory mandates into high-volume, reimbursed patient volume.

With nearly 90,000 Medicaid births and approximately 4 million Medicaid lives, Florida represents our largest reimbursed market opportunity to date.
-- Zhenya Lindgardt, President and Chief Executive Officer

2. High-Volume Physician Adoption Requires Twelve to Eighteen Months

Clinicians require significant time to transition from initial trial usage to making a novel diagnostic test a standard component of prenatal care. The commercial sales model relies on active field education and electronic record integrations to turn initial awareness into routine practice adoption.

Physicians moving from initial awareness and early interest to broad adoption and high-volume ordering is a process which we have seen take 12 months to 18 months.
-- Scott Gleason, Chief Financial Officer

3. Commercial Pilot Programs Build Pathways to National Managed Care Coverage

Securing private insurance coverage requires demonstrating real-world utility and cost savings beyond government programs. Running paid pilot trials with large private insurers helps generate health economic data, paving the way for eventual nationwide reimbursement policies.

We currently have 4 active pilot programs underway, including 2 with major national health plans and are in discussions regarding a potential multistate 2027 implementation with one of the nation's largest managed care organizations.
-- Tiffany Inglis, Chief Medical Officer

Looking Ahead

Commercial momentum is expanding as field teams activate state coverage wins, supported by $72.8 million in cash that funds operations into fiscal year 2029. Management is prioritizing sales coverage in reimbursed regions while cutting administrative overhead to maintain strict capital discipline across the business.

On an overall basis, we believe we will see flat or down operating expenses in 2027 while significantly increasing the size of our commercial team.
-- Scott Gleason, Chief Financial Officer

Long-term growth hinges on securing clinical guideline inclusion, establishing kit-based international expansion by 2027, and expanding state Medicaid coverage. Management is executing its strategy to scale its diagnostic platform across commercial and government health channels.

We're building the infrastructure, capabilities and partnerships necessary to support long-term growth while maintaining a strong focus on operational efficiency and shareholder value creation.
-- Zhenya Lindgardt, President and Chief Executive Officer

Should you buy stock in Sera Prognostics right now?

Before you buy stock in Sera Prognostics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sera Prognostics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
Author  Beincrypto
21 hours ago
AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
placeholder
3 Key Events in the Coming Week That Could Move AI Stocks and CryptoNvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
Author  Beincrypto
21 hours ago
Nvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
placeholder
Weekly Market Wrap: Nvidia Lost Its CEO, but AI Stocks Found New LeadersNvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
Author  Mark Garro
21 hours ago
Nvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
placeholder
Bitcoin’s Fall to $62,000 Sparks Market Manipulation ClaimsBitcoin plunged to nearly $62,000 on November 15, its lowest level since July. The drop wiped out months of gains and triggered more than $2 billion in liquidations.Now, several analysts claim that la
Author  Beincrypto
21 hours ago
Bitcoin plunged to nearly $62,000 on November 15, its lowest level since July. The drop wiped out months of gains and triggered more than $2 billion in liquidations.Now, several analysts claim that la
placeholder
Bitcoin Loses Key 200-Day Average: Is $67,000 Next?Bitcoin price fell below its 200-day moving average of $73,137 on Thursday. It’s one of the most closely watched indicators in crypto because it helps investors understand whether Bitcoin’s long-term
Author  Beincrypto
Nov 13, Fri
Bitcoin price fell below its 200-day moving average of $73,137 on Thursday. It’s one of the most closely watched indicators in crypto because it helps investors understand whether Bitcoin’s long-term
goTop
quote